Wunderman wins AstraZeneca's Faslodex

Pharmaceuticals marketer AstraZeneca has tapped Wunderman New York to launch a consumer campaign for Faslodex, a later-stage breast cancer prescription drug for women.

The direct marketing agency competed with CommonHealth and Digitas' Medical Broadcasting Company agency for the account. Billings were not disclosed.

"This helps us broaden our portfolio with their oncology division," said Steve Zammarchi, president/CEO of Wunderman New York. "We have to create awareness for the product in the direct-to-consumer marketplace."

Wunderman New York currently handles the Arimidex and Casodex/Zoladex brands, which are part of AstraZeneca's oncology medications.

A print campaign for Faslodex will begin this summer. Call to action and theme have not yet been disclosed.